EIMD Supplement Scorecard: What Recovery Claims Hold Up

Most supplements sold for post-workout recovery promise less soreness, lower inflammation, and faster return to training. The best available overview finds a much less glamorous result: across 24 nutritional interventions, none had high-certainty evidence for any exercise-induced muscle damage outcome. Moderate certainty was the ceiling.

That conclusion comes from a 2024 umbrella review by Talebi et al., which assessed 53 meta-analyses of randomized trials across 10 outcomes. A lower creatine kinase result or a better soreness score can be real without proving that an athlete will regain strength, power, or training capacity sooner. That distinction decides which products deserve a place in a recovery plan.

What the evidence actually supports

The umbrella review identified only two supplements with moderate-certainty evidence for objective blood markers of muscle damage. HMB reduced creatine kinase (CK) and lactate dehydrogenase (LDH). L-carnitine reduced CK and muscle soreness. CK, LDH, and myoglobin rise after damaging exercise because they are indirect markers of muscle-cell disruption; they are useful research endpoints, but they do not measure athletic readiness directly.

Several interventions reached moderate certainty for delayed-onset muscle soreness (DOMS): BCAAs, leaf extract, curcumin, ginseng, broader polyphenols, and anthocyanins. The review did not report standardized mean differences or 95% confidence intervals in its available abstract, so it cannot rank these options by effect size or tell readers whether a statistically detectable change would feel meaningful after a hard training session.

The scorecard therefore has a clear top tier, but not a miracle tier.

• Best evidence for biomarkers: HMB for CK and LDH; L-carnitine for CK.
• Best evidence for soreness plus a biomarker: L-carnitine.
• Moderate-certainty evidence for soreness: curcumin, ginseng, polyphenols, anthocyanins, BCAAs, and leaf extract.
• No high-certainty winner: every category remains limited by the underlying trials and reviews.

Root plants look useful—within limits

Plant-derived recovery supplements have their best case in a pooled analysis of curcumin, ginseng, ginger, and garlic. A 2022 systematic review and meta-analysis by Doma et al. combined 25 studies involving 353 participants and found statistically significant reductions in CK, LDH, myoglobin, and soreness at 24 and 48 hours after exercise (all p<0.01).

The inflammation results were more fleeting. The pooled interventions reduced inflammatory markers at 24 hours (p=0.02), but not at 48 hours (p=0.40). Biomarker and soreness changes persisted through 48 hours, which means an anti-inflammatory explanation alone does not account for the observed pattern. It does not establish a different mechanism, either.

The practical limitation is harder to ignore: the same meta-analysis found no statistically significant improvement in muscular performance recovery at either 24 or 48 hours (both p>0.05). Less soreness may improve comfort. It does not, on these data, show that the athlete can produce more force or power at the next session.

Reduced soreness and lower damage biomarkers are outcomes. Faster restoration of performance is the outcome most athletes are actually buying.

There is also a translation problem. Doma and colleagues pooled four distinct compounds and did not provide compound-specific effect sizes, doses, formulations, or timepoint-level estimates in the reported findings. "Root plants work" is not a dosing protocol. The umbrella review separately gave curcumin and ginseng moderate-certainty ratings for soreness, not for objective biomarkers. That is more precise than treating every root-plant product as interchangeable.

Curcumin depends on the formulation

Curcumin is the most studied individual compound in this group, but ordinary curcumin has poor oral bioavailability. A 2022 narrative review by Nanavati et al. identifies formulation as a major reason curcumin trials diverge. Piperine co-administration, phospholipid complexes, and hydrolyzed forms are not pharmacologically equivalent to plain curcumin powder.

A 2025 randomized trial by Helder et al. examined dose-response effects of hydrolyzed curcumin on recovery, inflammation, and oxidative stress after exercise-induced muscle damage in males. Its design addresses the formulation question directly, but it does not turn every curcumin product into the same intervention. The available summary does not provide a dose, effect size, confidence interval, or outcome-specific result, so no evidence-based product-level dosing recommendation follows from it.

Fish oil has a plausible mechanism and an unreliable record

Omega-3 supplements are often treated as automatic recovery insurance. The evidence does not justify that confidence. A 2021 systematic review by Anthony et al. evaluated 15 studies of fish oil or long-chain omega-3 supplementation lasting at least seven days, using eccentric exercise and DOMS outcomes. Only one study—6.7%—met the authors' methodological quality standards.

The recurring flaws mattered to the biological question. Many trials were too short for meaningful incorporation of EPA and DHA into erythrocyte membrane phospholipids, generally expected to require four or more weeks. Many also failed to establish baseline membrane omega-3 status, potentially mixing participants who were already replete with those who could respond. Dose and fatty-acid composition were often poorly described, while bias ratings were commonly unclear or medium.

The review noted an apparently favorable signal for DOMS and inflammatory markers, and the proposed pathway—changes in membrane phospholipids that may affect prostaglandin-mediated inflammatory signaling—is biologically plausible. Plausibility does not yield a trustworthy effect size. The review's real conclusion is narrower and more useful: the literature cannot quantify whether omega-3s improve DOMS reliably.

A subsequent 2023 randomized trial by Mackay et al. adds a direct negative result. In trained young males, four weeks of fish oil supplementation failed to alter muscle-damage indices or muscle-repair markers during acute recovery from eccentric exercise. Because the trial met the duration criterion that undermined many earlier studies, this null result cannot be dismissed as merely a too-short supplementation experiment. It applies specifically to trained young men and does not prove fish oil fails in every population, but it weakens the common DOMS claim.

Polyphenols and protein: promising categories, not shortcuts

The umbrella review's moderate-certainty soreness ratings for polyphenols and anthocyanins make tart cherry a reasonable research lead, not a settled product verdict. A 2021 tart cherry extract randomized trial by Hooper et al. studied 13 participants after intense resistance exercise and reported recovery benefits. A crossover design can reduce between-person confounding, but 13 participants cannot provide a stable standalone estimate. This trial supports the broader polyphenol question; it does not independently confirm tart cherry as a recovery supplement.

Plant protein deserves separate treatment. A 2025 systematic review by Govindasamy et al. examined plant-based proteins for recovery from resistance exercise-induced muscle damage in healthy young adults. It included 24 studies—22 randomized and two non-randomized—and evaluated sources such as soy, pea, rice, hemp, potato, and blends, generally dosed at 15 to 50 grams after resistance exercise. This is a developing evidence stream, not a basis for folding plant protein into the HMB or curcumin rankings above.

Why your response may differ from the average

Supplement trials average people whose damage responses differ before the supplement enters the picture. In a 2023 observational study by Pereira et al., 27 healthy men completed an acute strength-training session; 18 had the ACTN3 RR/RX genotype and nine had the XX genotype. The ACTN3 R577X polymorphism influenced the magnitude of muscle damage and inflammatory response. This does not show that a genotype determines who benefits from a given supplement. It does show why an average trial result can conceal different individual responses.

Safety also remains underdescribed in this recovery literature. The cited analyses do not provide adequate adverse-effect, interaction, or contraindication data for curcumin or ginseng at exercise-induced muscle-damage doses. That gap matters for people using anticoagulants or managing hormonal conditions, among others.

The practical verdict

If the goal is lower CK or LDH after damaging exercise, HMB and L-carnitine have the strongest available evidence tier. L-carnitine also has moderate-certainty support for reduced soreness. If soreness is the main concern and a plant-derived option is preferred, curcumin and ginseng have moderate-certainty evidence, while pooled root-plant research supports short-term reductions in soreness and several damage biomarkers. Choose curcumin formulations with bioavailability in mind, but do not pretend the evidence has settled the optimal form or dose.

Fish oil does not pass as an EIMD supplement today. Its mechanism is plausible, but 14 of 15 studies in one review failed its quality criteria, and a four-week randomized trial in trained young men found no benefit on measured damage or repair markers. Most important, no nutritional intervention in this evidence base has shown high-certainty evidence for faster functional performance recovery. The supplement shelf can sometimes make tomorrow's soreness less annoying. It has not yet shown that it can make tomorrow's training better.